1-2 of 2
Caterina Peraldo-Neia
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas

Giuliana Cavalloni, Caterina Peraldo-Neia, Ivana Sarotto, Loretta Gammaitoni, Giorgia Migliardi, Marco Soster, Serena Marchiò, Massimo Aglietta, Francesco Leone
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (7): 1528–1538.
https://doi.org/10.1158/1535-7163.MCT-11-1020
Published: 05 July 2012
View article titled, Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
Open the PDF for Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas in another window
Includes: Supplementary data
Journal Articles

Abstract A82: HHER2‐positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and become sensitive to the multitargeted kinase inhibitor sorafenib

Sonia Capellero, Giorgio Valabrega, Giuliana Cavalloni, Gianluca Zaccarello, Annalisa Petrelli, Giorgia Migliardi, Andrea Milani, Caterina Peraldo Neia, Loretta Gammaitoni, Francesco Favero, Aldo Moggio, Silvia Giordano, Massimo Aglietta, Filippo Montemurro
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A82.
https://doi.org/10.1158/1535-7163.TARG-09-A82
Published: 10 December 2009
View article titled, Abstract A82: HHER2‐positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and become sensitive to the multitargeted kinase inhibitor sorafenib